Dr. Debbie Lin, Director Corporate Development
Strategy & Development
Boehringer Ingelheim’s Corporate Strategy & Development department is the navigator of BI’s strategic direction and drives corporate steering by supporting current performance goals and identifying future opportunities.
Our team refines our corporate strategy as well as monitors, supports and challenges the strategies for our Business Units. Thereby, we identify growth opportunities inside and outside our core business, drive the management of the corporate strategy and portfolio, and foster efficiency through cross-functional alignment, governance and commitment in order to develop the best strategic plan. In all projects, we promote the outside-in perspective to achieve agility and enhanced competitiveness.
We anticipate and identify trends in the healthcare system potentially affecting and transforming the traditional pharmaceutical business model. We also identify and explore potential new solutions that are “beyond the pill”, for example holistic methods, predictive models, and health measures, in order to create a business model that is future-oriented, creating new revenue streams for Boehringer Ingelheim.
The pharmaceutical industry is changing rapidly, so that new business models for profitable growth are critical for success. Our strategic development projects and the tracking of strategy implementation are carried out in close cooperation with our Business Units within the framework of an annually coordinated strategic review process.